Neuronetics Past Earnings Performance

Past criteria checks 0/6

Neuronetics's earnings have been declining at an average annual rate of -3.8%, while the Medical Equipment industry saw earnings growing at 8.7% annually. Revenues have been growing at an average rate of 4.9% per year.

Key information

-3.8%

Earnings growth rate

9.6%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate4.9%
Return on equity-99.6%
Net Margin-37.6%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Here's Why Shareholders May Want To Be Cautious With Increasing Neuronetics, Inc.'s (NASDAQ:STIM) CEO Pay Packet

May 24
Here's Why Shareholders May Want To Be Cautious With Increasing Neuronetics, Inc.'s (NASDAQ:STIM) CEO Pay Packet

The Neuronetics, Inc. (NASDAQ:STIM) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 09
The Neuronetics, Inc. (NASDAQ:STIM) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Neuronetics: Reality Set In

May 09

Market Cool On Neuronetics, Inc.'s (NASDAQ:STIM) Revenues Pushing Shares 36% Lower

May 08
Market Cool On Neuronetics, Inc.'s (NASDAQ:STIM) Revenues Pushing Shares 36% Lower

Neuronetics (NASDAQ:STIM) Has Debt But No Earnings; Should You Worry?

May 01
Neuronetics (NASDAQ:STIM) Has Debt But No Earnings; Should You Worry?

Even With A 26% Surge, Cautious Investors Are Not Rewarding Neuronetics, Inc.'s (NASDAQ:STIM) Performance Completely

Mar 17
Even With A 26% Surge, Cautious Investors Are Not Rewarding Neuronetics, Inc.'s (NASDAQ:STIM) Performance Completely

Neuronetics: Modest Improvements Are Not Enough

Jan 30

Neuronetics, Inc. (NASDAQ:STIM) Soars 61% But It's A Story Of Risk Vs Reward

Dec 19
Neuronetics, Inc. (NASDAQ:STIM) Soars 61% But It's A Story Of Risk Vs Reward

Neuronetics, Inc.'s (NASDAQ:STIM) Shares Not Telling The Full Story

Jun 21
Neuronetics, Inc.'s (NASDAQ:STIM) Shares Not Telling The Full Story

Does Neuronetics (NASDAQ:STIM) Have A Healthy Balance Sheet?

May 10
Does Neuronetics (NASDAQ:STIM) Have A Healthy Balance Sheet?

Neuronetics: Growth To Capture, But Fairly Priced

Sep 06

Is Neuronetics (NASDAQ:STIM) Using Debt Sensibly?

Sep 06
Is Neuronetics (NASDAQ:STIM) Using Debt Sensibly?

Neuronetics gets FDA nod for its D-Tect accessory product for use to treat depression

Aug 29

Neuronetics GAAP EPS of -$0.39 beats by $0.02, revenue of $16.3M beats by $0.84M , revises FY guidance

Aug 02

Neuronetics stock soars 30% as FDA clears NeuroStar system for anxious depression

Jul 19

Is Neuronetics (NASDAQ:STIM) A Risky Investment?

Jun 08
Is Neuronetics (NASDAQ:STIM) A Risky Investment?

Is Neuronetics (NASDAQ:STIM) Weighed On By Its Debt Load?

Jan 19
Is Neuronetics (NASDAQ:STIM) Weighed On By Its Debt Load?

Revenue & Expenses Breakdown

How Neuronetics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:STIM Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2473-28729
31 Dec 2371-307310
30 Sep 2369-337310
30 Jun 2368-317211
31 Mar 2367-377510
31 Dec 2265-37759
30 Sep 2262-37738
30 Jun 2259-37717
31 Mar 2257-34677
31 Dec 2155-31638
30 Sep 2156-27598
30 Jun 2155-22529
31 Mar 2150-23488
31 Dec 2049-27519
30 Sep 2051-315311
30 Jun 2055-355813
31 Mar 2061-346214
31 Dec 1963-296014
30 Sep 1961-286012
30 Jun 1959-265810
31 Mar 1955-26559
31 Dec 1853-24528
30 Sep 1849-23488
30 Jun 1846-22448
31 Mar 1843-17397
31 Dec 1740-16368
31 Dec 1634-11298

Quality Earnings: STIM is currently unprofitable.

Growing Profit Margin: STIM is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: STIM is unprofitable, and losses have increased over the past 5 years at a rate of 3.8% per year.

Accelerating Growth: Unable to compare STIM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: STIM is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (5.5%).


Return on Equity

High ROE: STIM has a negative Return on Equity (-99.59%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.